Fwd: [Use of hospital discharge records to estimate the incidence of malignant mesotheliomas]

---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Sat, Aug 9, 2008 at 12:44 AM
Subject: [Use of hospital discharge records to estimate the incidence of malignant mesotheliomas]
To: mesothelioma77@gmail.com


[1]Epidemiol Prev. 2007 Mar-Jun; 31(2-3): 127-31
Stura A, Gangemi M, Mirabelli D

SETTING: cancer registries usually adopt strategies for active case finding. Interest in using administrative sources of data is rising OBJECTIVE: to assess the usefullness of Hospital discharge records (HDR) to supplement the traditional methods of case finding of the malignant mesothelioma (MM) Registry of the Piedmont Region. METHODS: HDRs have been used since 1996. We assessed the number of cases identified only through HDRs and their influence on MM incidence. RESULTS: cases identified through HDRs were about 10% of those with histologic confirmation of the diagnosis, 34% of those with cytologic confirmation, and 72% of those without morphologic examination. Cases diagnosed in hospitals located outside the region would have been easily (50%) missed. The age-standardised (standard: Italian pop. at the 1981 census) incidence rate of pleural MM increases from 2.2 to 2.7 per 100,000 per year among men, and from 1.1 to 1.2 among women, when including all cases identified from HDRs, irrespective of their diagnostic confirmation. Peritoneal MM incidence estimates are unaffected. Overall without access to the hospital discharge files, 179 cases out of 954 would not have been registered between 1996 and 2001. In the same calendar period 59 cases identified by means of active search by the Registry have not been found in the hospital discharge files. CONCLUSIONS: HDRs are useful in addition, but not in substitution, to active search of MM cases.



___
Source: http://www.hubmed.org/display.cgi?uids=18677861
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: MET as a target for treatment of chest tumors.

---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Sat, Aug 9, 2008 at 12:44 AM
Subject: MET as a target for treatment of chest tumors.
To: mesothelioma77@gmail.com


[1]Lung Cancer. 2008 Jul 29;
Cipriani NA, Abidoye OO, Vokes E, Salgia R

The receptor tyrosine kinase MET has been studied of a large variety of human cancers, including lung and mesothelioma. The MET receptor and its ligand HGF (hepatocyte growth factor) play important roles in cell growth, survival and migration, and dysregulation of the HGF-MET pathway leads to oncogenic changes including tumor proliferation, angiogenesis and metastasis. In small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and malignant pleural mesothelioma (MPM), MET is dysregulated via overexpression, constitutive activation, gene amplification, ligand-dependent activation, mutation or epigenetic mechanisms. New drugs targeted against MET and HGF are currently being investigated in vitro and in vivo, with promising results. These drugs function at a variety of steps within the HGF-MET pathway, including MET expression at the RNA or protein level, the ligand-receptor interaction, and tyrosine kinase function. This paper will review the structure, function, mechanisms of tumorigenesis, and potential for therapeutic inhibition of the MET receptor in lung cancer and mesothelioma.



___
Source: http://www.hubmed.org/display.cgi?uids=18672314
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Antibody-onconase conjugates: cytotoxicity and intracellular routing.

---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Sat, Aug 9, 2008 at 12:44 AM
Subject: Antibody-onconase conjugates: cytotoxicity and intracellular routing.
To: mesothelioma77@gmail.com


[1]Curr Pharm Biotechnol. 2008 Jun; 9(3): 226-30
Rybak SM

Onconase, a member of the pancreatic ribonuclease A superfamily, is currently in Phase III clinical trials for treatment of unresectable malignant mesothelioma. The anticancer effect of onconase may relate to its intracellular target, a non-coding RNA. Some non-coding RNAs are aberrantly expressed in cancer cells. This discovery is creating new interest in drugs that target RNA. Conjugating onconase to agents that recognize tumor associated molecules further increases its potency and specificity. Analysis of onconase activity when directed to two different internalizing and one non-internalizing receptor reveals that the ideal targeting agents would rapidly enter lysosomal compartments before onconase escaped to the cytosol. Antibody-onconase conjugates are effective in preclinical models, cause little non-specific toxicities in mice and have favorable formulation properties. Understanding the reason for their potency coupled with understanding novel RNA-based mechanisms of tumor cell death will lead to improved variations of targeted onconase.



___
Source: http://www.hubmed.org/display.cgi?uids=18673288
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes.

---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Sat, Aug 9, 2008 at 12:44 AM
Subject: Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes.
To: mesothelioma77@gmail.com


[1]Curr Pharm Biotechnol. 2008 Jun; 9(3): 215-25
Ardelt W, Shogen K, Darzynkiewicz Z

Rana pipiens oocytes contain two homologues of pancreatic ribonuclease A that are cytostatic and cytotoxic to human cancer cells. Extensively studied Onconase is in advanced Phase IIIb clinical trials against malignant mesothelioma, while Amphinase is a novel enzyme in pre-clinical development. Onconase is the smallest (104 amino acid residues) member of the ribonuclease A superfamily while Amphinase (114 residues) is the largest among amphibian ribonucleases. Both enzymes share the characteristic frog ribonucleases C-terminal disulfide bond but another signature of this group, the N-terminal pyroglutamate, an integral part of Onconase active site is not conserved in Amphinase. Although Onconase and Amphinase are weak catalysts their enzymatic activities are required for cytostatic and cytotoxic activity. While it was postulated that tRNA is the primary substrate of Onconase in vivo there is also extensive indirect evidence that suggests other RNA species, in particular micro RNAs, may actually be the critical target of these ribonucleases. The cytostatic effects of Onconase and Amphinase are manifested as cell arrest in the G(1) cell cycle phase. Apoptosis then follows involving activation of endonucleases(s), caspases, serine proteases and transglutaminase. Onconase was shown to be strongly synergistic when combined with numerous other antitumor modalities. Onconase and Amphinase are highly cationic molecules and their preferential toxicity towards cancer cells (having distinctly higher negative charge compared to normal cells) may depend on increased binding efficiency to the cell surface by electrostatic interactions.



___
Source: http://www.hubmed.org/display.cgi?uids=18673287
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: [Surgical treatment of peritoneal carcinomatosis with reduction surgery and perioperative chemotherapy]

---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Sat, Aug 9, 2008 at 12:44 AM
Subject: [Surgical treatment of peritoneal carcinomatosis with reduction surgery and perioperative chemotherapy]
To: mesothelioma77@gmail.com


[1]Rev Prat. 2008 May 15; 58(9): 940-3
Zinzindohoué F, Glehen O, Ferraz JM, Gilly F, Cuqnenc PH

So far, peritoneal carcinomatosis had been considered as the last progression stage of intra-abdominal cancers, and thus without any therapeutic recourse. During the last ten years, the association of tumour surgical resection and perioperative intraperitoneal chemotherapy (with or without hyperthermia) has proven to produce long term survival and even cure. This aggressive therapeutic strategy is associated with mortality and morbidity, which add to the mortality and morbidity of surgery and chemotherapy. It thus requires a careful patient selection conducted by specialized multidisciplinary teams. The main indications are peritoneal carcinomatosis on colorectal cancer, stomach cancer, ovarian cancer, pseudomyxoma and mesothelioma. The treatment can also be initiated secondarily, if carcinomatosis is detected during a procedure performed in a center where this type of treatment is not provided. An organ resection should thus be performed. The patient is then referred to a specialized center, either within the ten days following the procedure, or after three months, most of the time after an adjuvant therapy.



___
Source: http://www.hubmed.org/display.cgi?uids=18672658
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc